In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OctreoPharm Sciences GmbH

Division of Ipsen
www.octreopharmsciences.com

Latest From OctreoPharm Sciences GmbH

Deal Watch: AbbVie Moves Into Microbiome, Synthetic Biology With Synlogic Partnership

Mylan adds more than 900 over-the-counter and generic products to its portfolio with the $9.9bn acquisition of Meda. Astellas finalizes the pursuit of Ocata which it began last November.

BioPharmaceutical Deals

Ipsen’s U.S. Business Could Be Profitable In 2016, A Year Early

A turnaround in Ipsen’s U.S. business is underpinning a transformation at the European mid-sized pharmaceutical company, which is planning to narrow its focus to niche therapeutic areas including gastrointestinal endocrine tumors and antispasticity neurotoxins.

BioPharmaceutical Consumer

Ipsen’s U.S. Business Could Be Profitable In 2016, A Year Early

A turnaround in Ipsen’s U.S. business is underpinning a transformation at the European mid-sized pharmaceutical company, which is planning to narrow its focus to niche therapeutic areas including gastrointestinal endocrine tumors and antispasticity neurotoxins.

BioPharmaceutical Consumer

European Notebook: New Pricing Models; G7 On Clinical Data Transparency; Early Access For Opdivo

Novartis’s Jimenez calls for new outcomes-based pricing in Europe, and U.K. PM Cameron wants the results of vaccine clinical trials to be open and transparent post-Ebola, while patients gain pre-approval access to Bristol’s new PD-1 inhibitor.

BioPharmaceutical Europe
See All

Company Information

  • Industry
  • Medical Devices
    • Diagnostic Imaging Equipment & Supplies
      • Molecular Imaging
  • Pharmaceuticals
    • Radiopharmaceuticals, Contrast Agents
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Germany
  • Parent & Subsidiaries
  • Ipsen
  • Senior Management
  • Hakim Bouterfa, Phd, Mng. Dir.
    Jens Kaufmann, PhD, Head, Radiopharmaceutical Dev.
  • Contact Info
  • OctreoPharm Sciences GmbH
    Phone: (0)30 94893360
    Robert-Roessle-Strasse 10
    Bldg. B55
    Berlin, 13125
    Germany
Advertisement
Advertisement
UsernamePublicRestriction

Register